Syncona (SYNC) Q1 2027 TU earnings summary

Executive summary

• Achieved meaningful progress across the portfolio, including first patient dosed in Spur's Phase III pivotal trial and positive clinical updates from Resolution and Spur.

• Four key value inflection points expected by end of CY2026, with additional milestones through CY2028, positioning the portfolio for significant upside.

• Leadership changes and appointments across several portfolio companies to support strategic growth and operational execution.

Financial highlights

• Net assets at £1,038.1 million, 170.6p per share as of 30 June 2026, with a NAV per share return of 0.0% for the quarter.

• Life Science Portfolio valued at £866.7 million, up from £839.4 million, a 0.5% return in the quarter.

• Capital pool of £171.4 million, with £24.9 million deployed during the quarter, all into late-stage and clinical-stage companies.

Outlook and guidance

• Portfolio is well positioned to deliver significant upside, with potential for £250 million in proceeds to shareholders as key milestones are achieved.

• Four capital access milestones and four key value inflection points targeted by end of CY2026, with further milestones through CY2028.

• Mosaic Therapeutics adjusted its clinical study initiation to CY2027, reflecting a new strategic focus.